Innovative Technology Exonbio's SPIN technology for recombinant antibody development offers unique opportunities for clients seeking custom antibody solutions, especially in therapeutic and diagnostic applications.

COVID-19 Response The company's successful launch of SARS-CoV-2 spike monoclonal antibodies indicates a strong capacity for rapid development of pandemic-related diagnostic and therapeutic reagents, opening avenues for collaborations in infectious disease research.

Growing Market Presence With revenues ranging from one to ten million dollars, Exonbio is positioned as a competitive player in the biotech research segment, providing potential sales opportunities among mid-sized biotech and research organizations.

Targeted Service Offerings Exonbio’s expertise in recombinant proteins and monoclonal antibodies presents avenues for custom contract development services, particularly for companies needing specialized reagents for preclinical or clinical research.

Strategic Location Based in San Diego, a hub for biotech innovation, Exonbio has access to a robust network of biotech firms, research institutions, and funding sources, facilitating potential collaborations and sales channels within the region.